Background\n\nRecent work shows that ambient light intensity as low as 200 lux suppresses melatonin onset and that darkness duration, not just wavelength, determines melatonin length and downstream metabolic effects [1]. Evening dim light impairs glucose homeostasis and suppresses hepatic clock genes, independent of sleep quality [3], 4] and [5]. These data indicate that the circadian system interprets the length of night as a metabolic cue.\n\n## Hypothesis\n\nWe propose that the suprachiasmatic nucleus (SCN) translates darkness duration into a tonic inhibitory signal to the liver via the splanchnic sympathetic nervous system, suppressing gluconeogenic gene expression (PEPCK, G6Pase) and hepatic glucose output. This pathway operates independently of melanopsin-mediated phototransduction and melatonin secretion; thus, actual darkness, not merely blue‑light filtration, is required for metabolic circadian gating.\n\n## Mechanistic Rationale\n\n1. The SCN receives light information through intrinsically photosensitive retinal ganglion cells (ipRGCs) but also integrates darkness duration via rebound activity of GABAergic neurons during the dark phase.\n2. During prolonged darkness, SCN GABAergic output to the paraventricular nucleus (PVN) reduces excitatory drive to sympathetic preganglionic neurons, lowering norepinephrine release onto hepatic sympathetic terminals.\n3. Reduced hepatic sympathetic tone decreases β‑adrenergic‑cAMP‑PKA signaling, leading to diminished CREB‑dependent transcription of gluconeogenic enzymes.\n4. This model predicts that melatonin suppression or supplementation will not rescue the metabolic phenotype if darkness duration is shortened, because the SCN‑PVN‑sympathetic axis is the primary conduit.\n\n## Testable Predictions\n\n- Prediction 1: Mice with intact melanopsin but SCN‑specific lesion of GABAergic neurons will lose the darkness‑dependent suppression of hepatic PEPCK mRNA and exhibit elevated glucose tolerance test (GTT) area under the curve, despite normal melatonin profiles.\n- Prediction 2: Mice lacking melanopsin (Opn4‑/‑) but with intact SCN will retain normal darkness‑length regulation of hepatic gluconeogenesis, showing similar GTT improvements to wild‑type when exposed to extended dark periods.\n- Prediction 3: Pharmacological blockade of β‑adrenergic receptors in the liver will abolish the differences in glucose output between long‑dark and short‑dark conditions, confirming sympathetic mediation.\n\n## Experimental Design\n\n- Use three mouse groups: WT, Opn4‑/‑, and SCN‑VGAT‑Cre‑mediated GABA neuron ablation.\n- House animals in 12 h light:12 h dark (LD) versus 12 h light:6 h dark (short dark) for 2 weeks, maintaining identical light intensity (~200 lux) during the light phase.\n- Measure plasma melatonin to confirm phase shifts, perform GTT and insulin tolerance test (ITT), and collect liver tissue for qPCR of Pepck and G6pase and hepatic sympathetic neurotransmitter content (HPLC).\n- In a subset, treat with propranolol (β‑blocker) via osmotic pump to test sympathetic dependence.\n\n## Potential Implications\n\nIf validated, this hypothesis would re‑frame darkness as a metabolic therapeutic, suggesting that environmental designs ensuring sufficient uninterrupted dark periods (e.g., blackout bedrooms, shift‑work lighting schedules) could improve glycemic control beyond what blue‑light filters achieve. It also opens a avenue for targeting the SCN‑PVN‑sympathetic axis pharmacologically to mimic darkness‑induced metabolic benefits in individuals unable to obtain adequate night darkness.